Clinical utility of entecavir for chronic hepatitis B in Chinese patients

References

• Zhang C Zhong Y Guo L Strategies to prevent hepatitis B virus infection in China: immunization, screening, and standard medical practices Biosci Trends 2013 7 7 12 23524888
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association The guideline of prevention and treatment for chronic hepatitis B (2010 version) Zhonghua Gan Zang Bing Za Zhi 2011 19 13 24 Chinese 21272453
   PubMedGoogle Scholar
• Liaw YF Leung N Kao JH Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update Hepatol Int 2012 6 263 283
   Web of Science ®Google Scholar
• Ning LH Hao J Liao ZL Zhou YY Guo H Zhao XY A survey on the current trends in the management of hepatitis B in China Eur J Gastroenterol Hepatol 2012 24 884 889 22569081
   PubMed Web of Science ®Google Scholar
• Sun J Hou JL Management of chronic hepatitis B: experience from China J Viral Hepat 2010 17 Suppl 1 10 17 20586929
   PubMed Web of Science ®Google Scholar
• Anonymous IMS China Hospital Market Overview (CHPA, 2012) 2012
   Google Scholar
• Yang ZG Li YF Zhang L Wang J A comparative study of entecavir dispersible tablets with entecavir in chronic hepatitis B Journal of Bethune Military Medical College 2012 10 110 111
   Google Scholar
• Yang GY Zhang YG Chen K Chen J Zhu YJ Wang DW Initial treatment of entecavir dispersible tablets in chronic hepatitis B: analysis of 52 cases Chinese Medicine Guide 2011 9 371 373
   Google Scholar
• Lv C Zhang MQ Efficacy of entecavir dispersible tablets in HBeAg-positive chronic hepatitis B patients Journal of Medical Theory and Practice 2012 25 663 664
   Google Scholar
• Xie YM Zhu JR Zhou WG Cost-effectiveness analysis of domestic and imported entecavir in chronic hepatitis B Journal of Medical Theory and Practice 2012 25 2438 2439
   Google Scholar
• Xu JH Yu YY Si CW A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of HBeAg-negative chronic hepatitis B: results at week 48 Zhonghua Gan Zang Bing Za Zhi 2012 20 512 516 Chinese 23044236
   PubMedGoogle Scholar
• Luo J Li X Wu Y Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naive chronic hepatitis B patients in real life Int J Med Sci 2013 10 427 433 23471472
   PubMed Web of Science ®Google Scholar
• Yuen MF Seto WK Fung J Wong DK Yuen JC Lai CL Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety Am J Gastroenterol 2011 106 1264 1271 21364549
   PubMed Web of Science ®Google Scholar
• Chen J Han JH Liu C Short-term entecavir therapy of chronic severe hepatitis B Hepatobiliary Pancreat Dis Int 2009 8 261 266 19502165
   PubMed Web of Science ®Google Scholar
• Huang LH Qiu YW Hua HY The efficacy and safety of entecavir in patients with advanced schistosomiasis co-infected with hepatitis B virus Int J Infect Dis 2013 17 e606 e609 23490092
   PubMed Web of Science ®Google Scholar
• Madwar MA el Tahawy M Strickland GT The relationship between uncomplicated schistosomiasis and hepatitis B infection Trans R Soc Trop Med Hyg 1989 83 233 236 2514475
   PubMed Web of Science ®Google Scholar
• Wei L Hu S Hou J A novel estimation of the impact of treatment with entecavir on long-term mortality, morbidity, and health care costs of chronic hepatitis B in China Value in Health Regional Issues 2013 2 48 56
   Google Scholar
• Jin X Chen YP Yang YD Li YM Zheng L Xu CQ Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B PLoS One 2012 7 e34198 22479562
   PubMed Web of Science ®Google Scholar
• Yao G Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China J Antimicrob Chemother 2007 60 201 205 17556353
   PubMed Web of Science ®Google Scholar
• Hou J Jia J Wei L Entecavir versus other standard of care for up to 4 years in nucleos(t)ide-naive patients with CHB in Chinese clinical practice Abstract presented at the Third Asian Pacific Association for Study of the Liver June 6–10, 2013 Singapore
   Google Scholar
• Yao GB Ren H Xu DZ Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients J Viral Hepat 2010 17 Suppl 1 51 58 20586934
   PubMed Web of Science ®Google Scholar
• Yao G Chen C Lu W Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China Hepatol Int 2007 1 365 372 19669331
   PubMed Web of Science ®Google Scholar
• Ren FY Piao DM Piao XX A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B World J Gastroenterol 2007 13 4264 4267 17696259
   PubMed Web of Science ®Google Scholar
• Yao G Chen C Lu W Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naive Chinese patients with chronic hepatitis B: a randomized, multicenter study Hepatol Int 2008 2 486 493 19669324
   PubMed Web of Science ®Google Scholar
• Chen EQ Zhou TY Liu L A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: the 2-year results of a prospective study: adefovir versus entercavir for chronic hepatitis B Hepat Mon 2011 11 27 31 22087113
   PubMed Web of Science ®Google Scholar
• Wang LC Chen EQ Cao J De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naive HBeAg-negative chronic hepatitis B patients Hepatol Int 2011 5 671 676 21484140
   PubMed Web of Science ®Google Scholar
• Yan J Ren N Cai H The comparison of 96 weeks efficacy of lamivudine plus adefovir de novo combination therapy and entecavir mono-therapy for HBeAg-positive Hepatol Int 2013 7 Suppl 1 S1 S754
   Google Scholar
• Zheng MH Shi KQ Dai ZJ Ye C Chen YP A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients Clin Ther 2010 32 649 658 20435234
   PubMed Web of Science ®Google Scholar
• Tsai MC Chen CH Hung CH A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study Clin Microbiol Infect 5 10 2013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Wu B Li T Chen H Shen J Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis Value Health 2010 13 592 600 20561341
   PubMed Web of Science ®Google Scholar
• Lee KK Wu DB Chow PY Lee VW Li H Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong J Gastroenterol Hepatol 2012 27 1167 1174 22141402
   PubMed Web of Science ®Google Scholar
• Lau DT Khokhar MF Doo E Long-term therapy of chronic hepatitis B with lamivudine Hepatology 2000 32 828 834 11003630
   PubMed Web of Science ®Google Scholar
• Liaw YF Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B Antivir Chem Chemother 2001 12 Suppl 1 67 71 11594691
   PubMedGoogle Scholar
• Ono SK Kato N Shiratori Y The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance J Clin Invest 2001 107 449 455 11181644
   PubMed Web of Science ®Google Scholar
• Zoulim F Detection of hepatitis B virus resistance to antivirals J Clin Virol 2001 21 243 253 11397661
   PubMed Web of Science ®Google Scholar
• Liu Y Wang C Zhong Y Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection J Viral Hepat 2011 18 e29 e39 21392168
   PubMed Web of Science ®Google Scholar
• Yao G Zhou X Xu D Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China Hepatol Int 2007 1 373 381 19669332
   PubMed Web of Science ®Google Scholar
• Zhao P Wang C Huang L Xu D Li T Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B Antiviral Res 2012 96 100 104 22960601
   PubMed Web of Science ®Google Scholar
• Ha M Zhang G Diao S Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy Intern Med 2012 51 1509 1515 22728482
   PubMed Web of Science ®Google Scholar
• Lu JJ Liu K Ma YJ Wang J Chen E-Q Tang H Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil J Viral Hepat 2013 20 Suppl 1 40 45 23458523
   PubMed Web of Science ®Google Scholar
• Wang JC He LL Chen Q Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir Eur Rev Med Pharmacol Sci 2013 17 1162 1166 23690184
   PubMed Web of Science ®Google Scholar
• Xu XH Li GL Qin Y Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice Virol J 2013 10 162 23706010
   PubMed Web of Science ®Google Scholar
• Xing J Han T Liu L Entecavir 1.0 mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil Zhonghua Gan Zang Bing Za Zhi 2011 19 828 832 Chinese 22433304
   PubMedGoogle Scholar
• Wong GL Chan HL Mak CH Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis Hepatology 2 6 2013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Yang SC Lee CM Hu TH Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants J Antimicrob Chemother 2013 68 2154 2163 23620466
   PubMed Web of Science ®Google Scholar
• Wang CC Tseng KC Peng CY Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir J Gastroenterol Hepatol 2013 28 46 50 22989322
   PubMed Web of Science ®Google Scholar
• Basu PP Brown RSJr Entecavir for the treatment of chronic hepatitis B: A clinical update for the treatment of patients with decompensated cirrhosis Open J Intern Med 2012 2 53 61
   Google Scholar
• Liaw YF Raptopoulou-Gigi M Cheinquer H Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation Hepatology 2011 54 91 100 21503940
   PubMed Web of Science ®Google Scholar
• Liaw YF Sheen IS Lee CM Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease Hepatology 2011 53 62 72 21254162
   PubMed Web of Science ®Google Scholar
• Lok AS McMahon BJ Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations Hepatology 2004 39 857 861 14999707
   PubMed Web of Science ®Google Scholar
• Xie F Yan L Lu J Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis PLoS One 2013 8 e54773 23382964
   PubMed Web of Science ®Google Scholar
• Cui YL Yan F Wang YB Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure Dig Dis Sci 2010 55 2373 2380 20512414
   PubMed Web of Science ®Google Scholar
• Yan Y Mai L Zheng YB What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients? World J Gastroenterol 2012 18 4604 4609 22969236
   PubMed Web of Science ®Google Scholar
• Xie SB Zhu JY Ying Z Zeng LJ Chao M Lu MQ Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study Transplantation 2010 90 786 790 20703179
   PubMed Web of Science ®Google Scholar
• Cai CJ Lu MQ Chen YH Zhao H Li MR Chen GH Clinical study on prevention of HBV re-infection by entecavir after liver transplantation Clin Transplant 2012 26 208 215 21981656
   PubMed Web of Science ®Google Scholar
• Fung J Cheung C Chan SC Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation Gastroenterology 2011 141 1212 1219 21762659
   PubMed Web of Science ®Google Scholar
• Fung J Chan SC Cheung C Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B Am J Gastroenterol 2013 108 942 948 23629601
   PubMed Web of Science ®Google Scholar
• Liu CJ Chen PJ Chen DS Kao JH Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management Hepatol Int June 14 2011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Liang RH Lok AS Lai CL Chan TK Todd D Chiu EK Hepatitis B infection in patients with lymphomas Hematol Oncol 1990 8 261 270 1701155
   PubMed Web of Science ®Google Scholar
• Li HR Huang JJ Guo HQ Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy J Viral Hepat 2011 18 877 883 21054683
   PubMed Web of Science ®Google Scholar
• Chen X Cao Z Liu Y Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with alpha-interferon plus a nucleos(t)ide analog J Gastroenterol Hepatol 2012 27 481 486 22098411
   PubMed Web of Science ®Google Scholar
• Xu DZ Wang XY Shen XL Results of a Phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings J Hepatol 2013 9 450 456 23669281
   PubMed Web of Science ®Google Scholar